Patient and donor characteristics
| . | Overall . | Bw6/Bw6/non-A*32/*24 . | Bw6/Bw6/A*32 donor KIR3DL1pos . | Bw6/Bw6/A*24 donor KIR3DL1pos . | Bw6/Bw6/A*24 donor KIR3DL1neg . | |
|---|---|---|---|---|---|---|
| N | 604 | 451 | 25 | 110 | 18 | |
| GVHD prophylaxis, n (%) | ||||||
| CsA-based | 215 (35.6) | 162 (35.9) | 11 (44.0) | 38 (34.5) | 4 (22.2) | |
| Other | 55 (9.1) | 43 (9.5) | 1 (4.0) | 10 (9.1) | 1 (5.6) | |
| Tac-based | 334 (55.3) | 246 (54.5) | 13 (52.0) | 62 (56.4) | 13 (72.2) | |
| TBI-based conditioning, n (%) | ||||||
| Unknown | 2 (0.3) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| No | 309 (51.2) | 234 (51.9) | 15 (60.0) | 49 (44.5) | 11 (61.1) | |
| Yes | 293 (48.5) | 215 (47.7) | 10 (40.0) | 61 (55.5) | 7 (38.9) | |
| Recipient age, mean (SD), y | 40.82 (17.69) | 40.68 (17.78) | 43.09 (18.58) | 40.75 (17.74) | 41.66 (14.79) | |
| Donor age, mean (SD), y | 32.68 (13.24) | 32.40 (12.84) | 37.11 (12.74) | 33.00 (14.56) | 31.35 (15.19) | |
| Recipient CMV serostatus, n (%) | ||||||
| Unknown | 8 (1.3) | 5 (1.1) | 0 (0.0) | 3 (2.7) | 0 (0.0) | |
| Negative | 223 (36.9) | 174 (38.6) | 7 (28.0) | 34 (30.9) | 8 (44.4) | |
| Positive | 373 (61.8) | 272 (60.3) | 18 (72.0) | 73 (66.4) | 10 (55.6) | |
| Donor CMV serostatus (%) | ||||||
| Unknown | 45 (7.5) | 31 (6.9) | 2 (8.0) | 12 (10.9) | 0 (0.0) | |
| Negative | 399 (66.1) | 303 (67.2) | 18 (72.0) | 66 (60.0) | 12 (66.7) | |
| Positive | 160 (26.5) | 117 (25.9) | 5 (20.0) | 32 (29.1) | 6 (33.3) | |
| Graft source, n (%) | ||||||
| BM | 287 (47.5) | 211 (46.8) | 10 (40.0) | 57 (51.8) | 9 (50.0) | |
| PBSC | 309 (51.2) | 235 (52.1) | 14 (56.0) | 51 (46.4) | 9 (50.0) | |
| BM, PBSC | 8 (1.3) | 5 (1.1) | 1 (4.0) | 2 (1.8) | 0 (0.0) | |
| Conditioning intensity, n (%) | ||||||
| Unknown | 23 (3.8) | 19 (4.2) | 1 (4.0) | 3 (2.7) | 0 (0.0) | |
| Nonmyeloablative | 19 (3.3) | 15 (3.5) | 1 (4.2) | 3 (2.8) | 0 (0.0) | |
| Reduced intensity | 70 (12.0) | 52 (12.0) | 3 (12.5) | 12 (11.2) | 3 (16.7) | |
| Myeloablative | 492 (84.5) | 365 (84.3) | 20 (83.3) | 92 (86.0) | 15 (83.3) | |
| T-cell depletion, n (%) | ||||||
| Yes | 198 (33.1) | 155 (34.6) | 7 (29.2) | 30 (27.5) | 6 (33.3) | |
| No | 401 (66.4) | 293 (65.0) | 17 (68.0) | 79 (71.8) | 12 (66.7) | |
| Unknown | 5 (0.8) | 3 (0.6) | 1 (4.0) | 1 (0.9) | 0 (0.0) | |
| HLA match, n (%) | ||||||
| HLA 10/10 matched | 384 (63.6) | 293 (65.0) | 15 (60.0) | 62 (56.4) | 14 (77.8) | |
| HLA 9/10 matched | 220 (36.4) | 158 (35.0) | 10 (40.0) | 48 (43.6) | 4 (22.2) | |
| Year of transplant, n (%) | ||||||
| 2005-2014 | 363 (60.1) | 274 (60.8) | 13 (52.0) | 63 (57.3) | 13 (72.2) | |
| 1989-2005 | 241 (39.9) | 180 (39.2) | 12 (48.0) | 47 (42.7) | 5 (27.8) | |
| Disease status at HCT, n (%) | ||||||
| First complete remission | 247 (40.9) | 179 (39.7) | 10 (40.0) | 49 (44.5) | 9 (50.0) | |
| Second or later complete remission | 156 (25.8) | 118 (26.2) | 5 (20.0) | 25 (22.7) | 8 (44.4) | |
| No remission | 160 (26.5) | 122 (27.1) | 8 (32.0) | 29 (26.4) | 1 (5.6) | |
| Other/unknown | 41 (6.8) | 32 (7.1) | 2 (8.0) | 7 (6.4) | 0 (0.0) | |
| KIR2DS1 HLA-C1/C2 donor, n (%) | ||||||
| KIR2DS1neg/C1/x | 395 (65.4) | 300 (66.5) | 21 (84.0) | 73 (66.4) | 1 (5.6) | |
| KIR2DS1pos/C1/x | 185 (30.6) | 135 (29.9) | 4 (16.0) | 29 (26.4) | 17 (94.4) | |
| C2/C2 | 24 (4.0) | 16 (3.6) | 0 (0.0) | 8 (7.2) | 0 (0.0) | |
| . | Overall . | Bw6/Bw6/non-A*32/*24 . | Bw6/Bw6/A*32 donor KIR3DL1pos . | Bw6/Bw6/A*24 donor KIR3DL1pos . | Bw6/Bw6/A*24 donor KIR3DL1neg . | |
|---|---|---|---|---|---|---|
| N | 604 | 451 | 25 | 110 | 18 | |
| GVHD prophylaxis, n (%) | ||||||
| CsA-based | 215 (35.6) | 162 (35.9) | 11 (44.0) | 38 (34.5) | 4 (22.2) | |
| Other | 55 (9.1) | 43 (9.5) | 1 (4.0) | 10 (9.1) | 1 (5.6) | |
| Tac-based | 334 (55.3) | 246 (54.5) | 13 (52.0) | 62 (56.4) | 13 (72.2) | |
| TBI-based conditioning, n (%) | ||||||
| Unknown | 2 (0.3) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| No | 309 (51.2) | 234 (51.9) | 15 (60.0) | 49 (44.5) | 11 (61.1) | |
| Yes | 293 (48.5) | 215 (47.7) | 10 (40.0) | 61 (55.5) | 7 (38.9) | |
| Recipient age, mean (SD), y | 40.82 (17.69) | 40.68 (17.78) | 43.09 (18.58) | 40.75 (17.74) | 41.66 (14.79) | |
| Donor age, mean (SD), y | 32.68 (13.24) | 32.40 (12.84) | 37.11 (12.74) | 33.00 (14.56) | 31.35 (15.19) | |
| Recipient CMV serostatus, n (%) | ||||||
| Unknown | 8 (1.3) | 5 (1.1) | 0 (0.0) | 3 (2.7) | 0 (0.0) | |
| Negative | 223 (36.9) | 174 (38.6) | 7 (28.0) | 34 (30.9) | 8 (44.4) | |
| Positive | 373 (61.8) | 272 (60.3) | 18 (72.0) | 73 (66.4) | 10 (55.6) | |
| Donor CMV serostatus (%) | ||||||
| Unknown | 45 (7.5) | 31 (6.9) | 2 (8.0) | 12 (10.9) | 0 (0.0) | |
| Negative | 399 (66.1) | 303 (67.2) | 18 (72.0) | 66 (60.0) | 12 (66.7) | |
| Positive | 160 (26.5) | 117 (25.9) | 5 (20.0) | 32 (29.1) | 6 (33.3) | |
| Graft source, n (%) | ||||||
| BM | 287 (47.5) | 211 (46.8) | 10 (40.0) | 57 (51.8) | 9 (50.0) | |
| PBSC | 309 (51.2) | 235 (52.1) | 14 (56.0) | 51 (46.4) | 9 (50.0) | |
| BM, PBSC | 8 (1.3) | 5 (1.1) | 1 (4.0) | 2 (1.8) | 0 (0.0) | |
| Conditioning intensity, n (%) | ||||||
| Unknown | 23 (3.8) | 19 (4.2) | 1 (4.0) | 3 (2.7) | 0 (0.0) | |
| Nonmyeloablative | 19 (3.3) | 15 (3.5) | 1 (4.2) | 3 (2.8) | 0 (0.0) | |
| Reduced intensity | 70 (12.0) | 52 (12.0) | 3 (12.5) | 12 (11.2) | 3 (16.7) | |
| Myeloablative | 492 (84.5) | 365 (84.3) | 20 (83.3) | 92 (86.0) | 15 (83.3) | |
| T-cell depletion, n (%) | ||||||
| Yes | 198 (33.1) | 155 (34.6) | 7 (29.2) | 30 (27.5) | 6 (33.3) | |
| No | 401 (66.4) | 293 (65.0) | 17 (68.0) | 79 (71.8) | 12 (66.7) | |
| Unknown | 5 (0.8) | 3 (0.6) | 1 (4.0) | 1 (0.9) | 0 (0.0) | |
| HLA match, n (%) | ||||||
| HLA 10/10 matched | 384 (63.6) | 293 (65.0) | 15 (60.0) | 62 (56.4) | 14 (77.8) | |
| HLA 9/10 matched | 220 (36.4) | 158 (35.0) | 10 (40.0) | 48 (43.6) | 4 (22.2) | |
| Year of transplant, n (%) | ||||||
| 2005-2014 | 363 (60.1) | 274 (60.8) | 13 (52.0) | 63 (57.3) | 13 (72.2) | |
| 1989-2005 | 241 (39.9) | 180 (39.2) | 12 (48.0) | 47 (42.7) | 5 (27.8) | |
| Disease status at HCT, n (%) | ||||||
| First complete remission | 247 (40.9) | 179 (39.7) | 10 (40.0) | 49 (44.5) | 9 (50.0) | |
| Second or later complete remission | 156 (25.8) | 118 (26.2) | 5 (20.0) | 25 (22.7) | 8 (44.4) | |
| No remission | 160 (26.5) | 122 (27.1) | 8 (32.0) | 29 (26.4) | 1 (5.6) | |
| Other/unknown | 41 (6.8) | 32 (7.1) | 2 (8.0) | 7 (6.4) | 0 (0.0) | |
| KIR2DS1 HLA-C1/C2 donor, n (%) | ||||||
| KIR2DS1neg/C1/x | 395 (65.4) | 300 (66.5) | 21 (84.0) | 73 (66.4) | 1 (5.6) | |
| KIR2DS1pos/C1/x | 185 (30.6) | 135 (29.9) | 4 (16.0) | 29 (26.4) | 17 (94.4) | |
| C2/C2 | 24 (4.0) | 16 (3.6) | 0 (0.0) | 8 (7.2) | 0 (0.0) | |
BM, bone marrow; CMV, cytomegalovirus; CsA, cyclosporine A; PBSC, peripheral blood stem cell; SD, standard deviation; Tac, tacrolimus; TBI, total body irradiation.